Candonilimab

Generic Name: Candonilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2394841-59-7

Unique Ingredient Identifier: 6FYG1DS4NW

Background: Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

Indication: 用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Not Applicable

Not yet recruiting

Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma
II-IIIB Stages

Interventions: Drug: Cadonilimab
Radiation: radiotherapy
Drug: carboplatin, paclitaxel

First Posted Date: 2024-12-04

Last Posted Date: 2024-12-04

Lead Sponsor: First Affiliated Hospital of Ningbo University

Target Recruit Count: 20

Registration Number: NCT06715501

IN10018 with Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial

Phase 2

Not yet recruiting

Conditions: Cervical Adenocarcinoma

Interventions: Drug: IN10018
Drug: Nab-paclitaxel
Drug: Cadonilimab

First Posted Date: 2024-10-23

Last Posted Date: 2024-10-23

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 25

Registration Number: NCT06654011

Locations: 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Phase 1

Recruiting

Conditions: Metastatic HER2 Positive Gastroesophageal Junction Cancer

Interventions: Drug: cadonilimab
Drug: Trastuzumab
Drug: Disitamab Vedotin
Drug: XELOX
Drug: mFOLFOX6

First Posted Date: 2024-10-21

Last Posted Date: 2024-10-21

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 90

Registration Number: NCT06650332

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients

Phase 1

Not yet recruiting

Conditions: RCC
Kidney Cancer
Renal Cell Carcinoma

Interventions: Drug: Vorolanib
Drug: cadonilimab

First Posted Date: 2024-08-29

Last Posted Date: 2024-08-29

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 37

Registration Number: NCT06577961

An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

Phase 2

Not yet recruiting

Conditions: Recurrent Ovarian Cancer

Interventions: Drug: AK112
Drug: AK104
Drug: Chemotherapy

First Posted Date: 2024-08-19

Last Posted Date: 2024-08-19

Lead Sponsor: Akeso

Target Recruit Count: 172

Registration Number: NCT06560112

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Not Applicable

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: Cadonilimab
Radiation: SBRT

First Posted Date: 2024-08-13

Last Posted Date: 2024-08-13

Lead Sponsor: Liu Huang

Target Recruit Count: 80

Registration Number: NCT06551207

Locations: 🇨🇳
Huazhong University of Science and Technology, Wuhan, Hubei, China

Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer

Phase 3

Not yet recruiting

Conditions: Chemotherapy
Efficacy
Safety
Advanced Ovarian Cancer
AK104(PD-1/CTLA-4 Bispecial Antibody)

Interventions: Drug: AK104

First Posted Date: 2024-08-07

Last Posted Date: 2024-08-07

Lead Sponsor: Anhui Provincial Hospital

Target Recruit Count: 100

Registration Number: NCT06542549

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Phase 2

Recruiting

Conditions: Endometrial Neoplasms
Neoplasm Metastasis
Neoplasm Recurrence, Local

Interventions: Drug: Paclitaxel and Cisplatin
Drug: Cadonilimab
Radiation: Radiotherapy

First Posted Date: 2024-08-01

Last Posted Date: 2024-08-01

Lead Sponsor: Shandong Cancer Hospital and Institute

Target Recruit Count: 30

Registration Number: NCT06532539

Locations: 🇨🇳
Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

A Phase Ib/II Study of AK112 (PD-1/VEGF Bispecific Antibody) in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC).

Phase 1

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: AK112
Drug: Sintilimab Injection
Drug: AK130
Drug: AK127
Drug: Bevacizumab biosimilar
Drug: Cadonilimab

First Posted Date: 2024-07-31

Last Posted Date: 2024-07-31

Lead Sponsor: Akeso

Target Recruit Count: 280

Registration Number: NCT06530251

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital), Jinan, Shandong, China

Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Phase 2

Recruiting

Conditions: Cervical Cancer

Interventions: Drug: Cadonilimab

First Posted Date: 2024-07-22

Last Posted Date: 2024-07-22

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 29

Registration Number: NCT06511726

Locations: 🇨🇳
Sun Yat-sen Memorial hosipital, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy